Skip to main content

Table 3 Progression-free survival and overall survival by LCS6 genotype and treatment

From: Let-7 miRNA-binding site polymorphism in the KRAS 3UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab

LCS6 genotype N Arm Median months 95% CI Interaction P value
Progression-free survival
Wild-type 154 A 7.9 7.2-8.5 0.63
297 B+C 7.7 7.2-8.3
Variant 26 A 7.7 3.8 – 11.6
58 B+C 8.5 7.0-10.0
Overall survival
Wild-type 154 A 20.4 16.5 – 24.2 0.50
297 B+C 18.9 16.9 – 20.9
Variant 26 A 22.3 13.2 – 31.4
  58 B+C 23.5 19.9 – 27.1